The Payer Landscape is Evolving -- But Change is Slow
Patty Zipfel offered her contributions to the PM360 article, The Payer Landscape is Evolving — But Change is Slow.
Here’s an excerpt:
Patty Zipfel, Vice President, Scientific Strategy at MicroMass Communications, Inc. agrees about the importance of collecting real-world evidence, she also advises pharma companies not to ignore methods to maximize real-world outcomes early on.
“Complex factors beyond the clinical efficacy and safety of a product–influenced by provider and patient behaviors and perceptions–can impact drug utilization and outcomes in the real world,” Zipfel adds. “For example, the patients’ ability to cope with a condition or method of therapy administration, patient-provider communication, and provider perceptions related to patient identification can impact the use and outcomes of a brand. By addressing real-world factors, pharma can improve outcomes, which will benefit the entire pharma ecosystem.”